Sublocade (buprenorphine) is a brand-name extended-release injection that’s prescribed for opioid use disorder. Sublocade has interactions with alcohol, some other drugs, and certain supplements.

Sublocade?是一种基于PLGA的“原位”形成植入物，旨在持续释放丁丙诺啡（一种部分μ-阿片受体激动剂），采用每月一次的给药方案用于治疗中度至重度的阿片类药物使用障碍（OUD）。与其他基于悬浮液的“原位”形成植入物不同，这些植入物中的药物晶体分散在 ...

Sublocade (buprenorphine) is a brand-name prescription medication. The Food and Drug Administration (FDA) has approved it to treat opioid use disorder in adults, as part of a complete treatment ...

If your doctor recommends treatment for opioid use disorder (OUD), they might prescribe Sublocade (buprenorphine). Sublocade is a prescription drug that’s used to treat OUD. This article describes the ...

Sublocade (buprenorphine) is a prescription drug that’s used to treat opioid use disorder. Sublocade can cause side effects that range from mild to serious. Examples include injection site reaction, ...

Rapid initiation Protocol: Healthcare providers can now initiate treatment with SUBLOCADE after a single dose of transmucosal buprenorphine and a one-hour observation period to confirm ...

Rates of non-fatal overdose events following SUBLOCADE treatment was lower compared to daily opioid agonist therapy. Data published in the Journal of Addition Medicine Given the naturalistic, ...

Rapid Initiation Protocol Reduces Time to Treatment with SUBLOCADE ® From One Week to One Hour, A Significant Advancement in the Treatment of Moderate to Severe Opioid Use Disorder (OUD) These FDA ...

PDUFA date set for February 7, 2025 If approved by the FDA, label would expand to include alternative injection sites in the thigh, buttock and back of the arm for induction and maintenance as well as ...